BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 27, 2024
See today's BioWorld
Home
» Kos Enters Cardio Area, Gets Biovail Products For $104M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Kos Enters Cardio Area, Gets Biovail Products For $104M
May 4, 2005
By
Karen Carey
No Comments
Getting a stronger foothold in the cardiovascular therapeutic area, Kos Pharmaceuticals Inc. paid $104 million in cash to Biovail Corp. for U.S. sales and marketing rights to Cardizem LA. (BioWorld Today)
BioWorld